Evangelos D Michelakis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7557888/publications.pdf

Version: 2024-02-01

98 papers	13,780 citations	31976 53 h-index	42399 92 g-index
98 all docs	98 docs citations	98 times ranked	13550 citing authors

#	Article	IF	Citations
1	A Mitochondria-K+ Channel Axis Is Suppressed in Cancer and Its Normalization Promotes Apoptosis and Inhibits Cancer Growth. Cancer Cell, 2007, 11, 37-51.	16.8	1,374
2	Metabolic Modulation of Glioblastoma with Dichloroacetate. Science Translational Medicine, 2010, 2, 31ra34.	12.4	606
3	Inflammation, Growth Factors, and Pulmonary Vascular Remodeling. Journal of the American College of Cardiology, 2009, 54, S10-S19.	2.8	605
4	Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial Hypertension. Circulation, 2002, 105, 2398-2403.	1.6	586
5	An Abnormal Mitochondrialâ€“Hypoxia Inducible Factor-1Î±â€“Kv Channel Pathway Disrupts Oxygen Sensing and Triggers Pulmonary Arterial Hypertension in Fawn Hooded Rats. Circulation, 2006, 113, 2630-2641.	1.6	530
6	Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility. Circulation, 2007, 116, 238-248.	1.6	486
7	Relevant Issues in the Pathology and Pathobiology of Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D4-D12.	2.8	465
8	A Nuclear Pyruvate Dehydrogenase Complex Is Important for the Generation of Acetyl-CoA and Histone Acetylation. Cell, 2014, 158, 84-97.	28.9	463
9	Comprehensive Invasive and Noninvasive Approach to the Right Ventricleâ€“Pulmonary Circulation Unit. Circulation, 2009, 120, 992-1007.	1.6	429
10	Dichloroacetate Prevents and Reverses Pulmonary Hypertension by Inducing Pulmonary Artery Smooth Muscle Cell Apoptosis. Circulation Research, 2004, 95, 830-840.	4.5	416
11	Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial Hypertension. Circulation, 2003, 108, 2066-2069.	1.6	341
12	Dichloroacetate, a Metabolic Modulator, Prevents and Reverses Chronic Hypoxic Pulmonary Hypertension in Rats. Circulation, 2002, 105, 244-250.	1.6	340
13	The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 11418-11423.	7.1	332
14	Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. Journal of Clinical Investigation, 2005, 115, 1479-1491.	8.2	323
15	Metabolic control of epigenetics in cancer. Nature Reviews Cancer, 2016, 16, 694-707.	28.4	317
16	Diversity in Mitochondrial Function Explains Differences in Vascular Oxygen Sensing. Circulation Research, 2002, 90, 1307-1315.	4.5	279
17	The Metabolic Theory of Pulmonary Arterial Hypertension. Circulation Research, 2014, 115, 148-164.	4.5	244
18	Metabolic Enzymes Moonlighting in the Nucleus: Metabolic Regulation of Gene Transcription. Trends in Biochemical Sciences, 2016, 41, 712-730.	7.5	227

#	Article	IF	Citations
19	Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e15-e43.	5.6	220
20	Role for DNA Damage Signaling in Pulmonary Arterial Hypertension. Circulation, 2014, 129, 786-797.	1.6	211
21	Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology. Frontiers in Oncology, 2013, 3, 38.	2.8	208
22	Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. Science Translational Medicine, 2017, 9, .	12.4	206
23	The Metabolic Basis of Pulmonary Arterial Hypertension. Cell Metabolism, 2014, 19, 558-573.	16.2	194
24	Fatty Acid Oxidation and Malonyl-CoA Decarboxylase in the Vascular Remodeling of Pulmonary Hypertension. Science Translational Medicine, 2010, 2, 44ra58.	12.4	193
25	The Role of Nogo and the Mitochondriaâ€“Endoplasmic Reticulum Unit in Pulmonary Hypertension. Science Translational Medicine, 2011, 3, 88ra55.	12.4	193
26	Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension. New England Journal of Medicine, 2009, 361, 1864-1871.	27.0	192
27	Mitochondria in Vascular Health and Disease. Annual Review of Physiology, 2013, 75, 95-126.	13.1	192
28	A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension. Journal of Molecular Medicine, 2013, 91, 1315-1327.	3.9	178
29	Obesity-induced lysine acetylation increases cardiac fatty acid oxidation and impairs insulin signalling. Cardiovascular Research, 2014, 103, 485-497.	3.8	175
30	Downregulation of MicroRNA-126 Contributes to the Failing Right Ventricle in Pulmonary Arterial Hypertension. Circulation, 2015, 132, 932-943.	1.6	173
31	Sirtuin 3 Deficiency Is Associated with Inhibited Mitochondrial Function and Pulmonary Arterial Hypertension in Rodents and Humans. Cell Metabolism, 2014, 20, 827-839.	16.2	170
32	O ₂ Sensing in the Human Ductus Arteriosus. Circulation Research, 2002, 91, 478-486.	4.5	154
33	Impairment of hypoxic pulmonary vasoconstriction in mice lacking the voltageâ€gated potassium channel Kv1.5. FASEB Journal, 2001, 15, 1801-1803.	0.5	138
34	Attenuating Endoplasmic Reticulum Stress as a Novel Therapeutic Strategy in Pulmonary Hypertension. Circulation, 2013, 127, 115-125.	1.6	138
35	Emerging Concepts and Translational Priorities in Pulmonary Arterial Hypertension. Circulation, 2008, 118, 1486-1495.	1.6	133
36	Absence of Malonyl Coenzyme A Decarboxylase in Mice Increases Cardiac Glucose Oxidation and Protects the Heart From Ischemic Injury. Circulation, 2006, 114, 1721-1728.	1.6	131

#	Article	IF	Citations
37	Hypoxic pulmonary vasoconstriction: redox regulation of O2-sensitive K+ channels by a mitochondrial O2-sensor in resistance artery smooth muscle cells. Journal of Molecular and Cellular Cardiology, 2004, 37, 1119-36.	1.9	129
38	Uncoupling Protein 2 Deficiency Mimics the Effects of Hypoxia and Endoplasmic Reticulum Stress on Mitochondria and Triggers Pseudohypoxic Pulmonary Vascular Remodeling and Pulmonary Hypertension. Circulation Research, 2013, 113, 126-136.	4.5	114
39	Dehydroepiandrosterone Reverses Systemic Vascular Remodeling Through the Inhibition of the Akt/GSK3-Î²/NFAT Axis. Circulation, 2009, 120, 1231-1240.	1.6	107
40	A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors. Investigational New Drugs, 2015, 33, 603-610.	2.6	105
41	A miR-208â€“Mef2 Axis Drives the Decompensation of Right Ventricular Function in Pulmonary Hypertension. Circulation Research, 2015, 116, 56-69.	4.5	101
42	Mechanical Stiffness Controls Dendritic Cell Metabolism and Function. Cell Reports, 2021, 34, 108609.	6.4	98
43	Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFÎ± contributes to the pathogenesis of pulmonary arterial hypertension. Journal of Molecular Medicine, 2011, 89, 771-783.	3.9	96
44	The role of mitochondria in pulmonary vascular remodeling. Journal of Molecular Medicine, 2010, 88, 1003-1010.	3.9	94
45	A dynamic and chamber-specific mitochondrial remodeling in right ventricular hypertrophy can be therapeutically targeted. Journal of Thoracic and Cardiovascular Surgery, 2008, 136, 168-178.e3.	0.8	89
46	Mitochondrial HSP90 Accumulation Promotes Vascular Remodeling in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 90-103.	5.6	75
47	Endothelin Axis Is Upregulated in Human and Rat Right Ventricular Hypertrophy. Circulation Research, 2013, 112, 347-354.	4.5	71
48	An Official American Thoracic Society Statement: Pulmonary Hypertension Phenotypes. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 345-355.	5.6	70
49	Pulmonary Arterial Hypertension: Challenges in Translational Research and a Vision for Change. Science Translational Medicine, 2013, 5, 208sr5.	12.4	69
50	Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase. European Urology, 2016, 69, 734-744.	1.9	66
51	Spatio-Temporal Diversity of Apoptosis Within the Vascular Wall in Pulmonary Arterial Hypertension. Circulation Research, 2006, 98, 172-175.	4.5	65
52	Effect of Fatty Acids on Human Bone Marrow Mesenchymal Stem Cell Energy Metabolism and Survival. PLoS ONE, 2015, 10, e0120257.	2.5	60
53	The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension. Heart Failure Reviews, 2003, 8, 5-21.	3.9	57
54	An Official American Thoracic Society Workshop Report: Obesity and Metabolism. An Emerging Frontier in Lung Health and Disease. Annals of the American Thoracic Society, 2017, 14, 1050-1059.	3.2	45

#	Article	IF	Citations
55	Exogenous Hydrogen Sulfide (H2S) Protects Alveolar Growth in Experimental O2-Induced Neonatal Lung Injury. PLoS ONE, 2014, 9, e90965.	2.5	44
56	An evidence-based approach to the management of pulmonary arterial hypertension. Current Opinion in Cardiology, 2006, 21, 385-392.	1.8	39
57	Heterogenous impairment of Î± cell function in type 2 diabetes is linked to cell maturation state. Cell Metabolism, 2022, 34, 256-268.e5.	16.2	39
58	Mitochondrial Medicine. Circulation, 2008, 117, 2431-2434.	1.6	38
59	New insights for the diagnosis and management of right ventricular failure, from molecular imaging to targeted right ventricular therapy. Current Opinion in Cardiology, 2010, 25, 131-140.	1.8	36
60	THE PATHOBIOLOGY OF PULMONARY HYPERTENSION. Clinics in Chest Medicine, 2001, 22, 419-432.	2.1	33
61	An evidence-based approach to the management of pulmonary arterial hypertension. Current Opinion in Cardiology, 2006, 21, 526-527.	1.8	33
62	Myocardial Functional Decline During Prolonged Ex Situ Heart Perfusion. Annals of Thoracic Surgery, 2019, 108, 499-507.	1.3	32
63	Reduced Right Ventricular Native Myocardial T1 in Anderson-Fabry Disease: Comparison to Pulmonary Hypertension and Healthy Controls. PLoS ONE, 2016, 11, e0157565.	2.5	30
64	Emerging Therapies and Future Directions in Pulmonary Arterial Hypertension. Canadian Journal of Cardiology, 2015, 31, 489-501.	1.7	29
65	Pulmonary Arterial Hypertension. Circulation Research, 2014, 115, 109-114.	4.5	28
66	Gene transfer and metabolic modulators as new therapies for pulmonary hypertension. Advances in Experimental Medicine and Biology, 2001, 502, 401-418.	1.6	28
67	Metabolic modulation of cancer: a new frontier with great translational potential. Journal of Molecular Medicine, 2015, 93, 127-142.	3.9	27
68	MRI. Chest, 2007, 132, 2-5.	0.8	26
69	A Central Role for Oxygen-Sensitive K+ Channels and Mitochondria in the Specialized Oxygen-Sensing System. Novartis Foundation Symposium, 2008, , 157-175.	1.1	24
70	MFN2-driven mitochondria-to-nucleus tethering allows a non-canonical nuclear entry pathway of the mitochondrial pyruvate dehydrogenase complex. Molecular Cell, 2022, 82, 1066-1077.e7.	9.7	23
71	The NO â" K+ Channel Axis in Pulmonary Arterial Hypertension. Advances in Experimental Medicine and Biology, 2003, 543, 293-322.	1.6	20
72	A Global Pulmonary Arterial Hypertension Registry: Is It Needed? Is It Feasible?. Chest, 2010, 137, 95S-101S.	0.8	17

#	Article	IF	Citations
73	A Paradigm Shift Is Needed in the Field of Pulmonary Arterial Hypertension for Its Entrance Into the Precision Medicine Era. Circulation Research, 2016, 119, 1276-1279.	4.5	16
74	Pioglitazone inhibits HIF-1Î±-dependent angiogenesis in rats by paracrine and direct effects on endothelial cells. Journal of Molecular Medicine, 2014, 92, 497-507.	3.9	14
75	Quantification of lung water in heart failure using cardiovascular magnetic resonanceÂimaging. Journal of Cardiovascular Magnetic Resonance, 2019, 21, 58.	3.3	14
76	Anorectic drugs and vascular disease:. Vascular Pharmacology, 2002, 38, 51-59.	2.1	13
77	The metabolic basis of vascular oxygen sensing: diversity, compartmentalization, and lessons from cancer. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 295, H928-H930.	3.2	13
78	The Estrogen Puzzle in Pulmonary Arterial Hypertension. Circulation, 2012, 126, 1016-1019.	1.6	13
79	A Phase-2 NIH-sponsored Randomized Clinical Trial of Rituximab in Scleroderma-associated Pulmonary Arterial Hypertension Did Not Reach Significance for Its Endpoints: End of Story? Not So Fast!. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 123-125.	5.6	9
80	A central role for oxygen-sensitive K+ channels and mitochondria in the specialized oxygen-sensing system. Novartis Foundation Symposium, 2006, 272, 157-71; discussion 171-5, 214-7.	1.1	9
81	Oral treprostinil improves pulmonary vascular compliance in pulmonary arterial hypertension. Respiratory Medicine, 2022, 193, 106744.	2.9	8
82	The Role of Doppler Echocardiography in Pulmonary Artery Hypertension. Chest, 2011, 139, 973-975.	0.8	7
83	F 2 -Isoprostanes. Chest, 2012, 142, 816-820.	0.8	7
84	SNPs for Genes Encoding the Mitochondrial Proteins Sirtuin3 and Uncoupling Protein 2 Are Associated With Disease Severity, Type 2 Diabetes, and Outcomes in Patients With Pulmonary Arterial Hypertension and This Is Recapitulated in a New Mouse Model Lacking Both Genes. Journal of the American Heart Association, 2021, 10, e020451.	3.7	7
85	Immunity Comes to Play in the â€œSex Paradoxâ€•of Pulmonary Arterial Hypertension. Circulation Research, 2018, 122, 1635-1637.	4.5	6
86	A reversible metabolic stress-sensitive regulation of CRMP2A orchestrates EMT/stemness and increases metastatic potential in cancer. Cell Reports, 2022, 38, 110511.	6.4	6
87	Addressing Complexity in Pulmonary Hypertension. Circulation Research, 2015, 116, 1732-1735.	4.5	4
88	Extended Bridge to Heart and Lung Transplantation Using Pumpless Extracorporeal Lung Assist. Canadian Journal of Cardiology, 2017, 33, 950.e11-950.e13.	1.7	4
89	Measurement of Nitric Oxide and Nitric Oxide Synthase Activity. , 1999, , 163-185.		4
90	Interaction with p53 explains a pro-proliferative function for VHL in cancer. Journal of Molecular Medicine, 2020, 98, 1269-1278.	3.9	3

#	Article	IF	Citations
91	G-protein-coupled receptors and pulmonary arterial hypertension (PAH). Drug Discovery Today: Disease Models, 2012, 9, e109-e117.	1.2	1
92	Response to Lazarus. Circulation Research, 2014, 114, e31.	4.5	1
93	Cell-Based Gene Therapy in Pulmonary Arterial Hypertension. Circulation Research, 2015, 117, 596-598.	4.5	1
94	Atrial Shunt Devices in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction and the Pulmonary Circulation: Promises and Concerns. Circulation, 2022, 145, 1605-1608.	1.6	1
95	PVDOMICS Drive the Pulmonary Hypertension Field Into the Precision Medicine Era. Circulation Research, 2017, 121, 1106-1108.	4.5	0
96	Oxygen Sensing in the Pulmonary Circulation. Circulation Research, 2017, 121, 323-325.	4.5	0
97	The time has come to pull renal cancerâ€™s sweet tooth. Translational Cancer Research, 2019, 8, S156-S161.	1.0	0
98	Changing cell fate in the wall of pulmonary arteries. Science Translational Medicine, 2022, 14, eabq1908.	12.4	0